1 week ago
2
peterschreiber.media/iStock via Getty Images
Amgen (NASDAQ:AMGN) and Zai Lab (NASDAQ:ZLAB) said on Monday that a late-stage trial testing the combination of bemarituzumab and chemotherapy for treating gastric cancer has successfully met its main goal of improving overall survival during an interim analysis.
Zai Lab
English (US) ·